Why would any team decide to trade away its best defensive player who still has a year left on his contract? “The question then becomes what you’re willing to take for him.” These two companies don’t have recurring revenues to rely on. Wall Street closed mostly lower on Tuesday owing to a record-high resurgence of coronavirus in the United States and Europe.
The Patriots are in an unfamiliar position, sitting at a record of 2-4 seven weeks into the season. After suffering a 33-6 loss at home against Jimmy Garoppolo and the San Francisco 49ers last Sunday, New England finds itself two games back in the loss column of the AFC East-leading Buffalo Bills. The Patriots have a tough schedule ahead of them, starting with a road trip to upstate New York on Sunday to take on the Bills, in what could very well dictate how the rest of New England’s season goes.
If the Patriots lose to the Bills on Sunday, putting them at a 2-5 record at the halfway point of the season, it will be time for the team to consider trading away players to recoup draft assets for next year and beyond.
One player in particular comes to mind when thinking of which player on the New England roster could net a strong return in a trade.
Stephon Gilmore, last year’s Defensive Player of the Year, has one year remaining on the free agent deal he signed with the Patriots back in 2017, and after restructuring his contract this summer– in which he received a $5 million pay raise this season– Gilmore carries a $17.1 million cap hit in 2021.
If New England decides to punt on this season and acquire draft picks to build for the future, trading Gilmore would bring back the greatest return out of any player on the roster.
The Patriots have reportedly already floated Gilmore’s name in trade talks multiple times, dating back to the offseason, according to Albert Breer of The MMQB.
Why would any team decide to trade away its best defensive player who still has a year left on his contract?
If the team gets the sense that Gilmore is going to want a new contract after this season, and doesn’t think that giving a big contract to a cornerback who will be 31 years old at the start of that next contract is a smart investment, it would make sense to gauge Gilmore’s value on the trade market.
The speculation about Gilmore wanting a new contract is bolstered by the team essentially giving Gilmore a cash advance on this season after Gilmore was “excused” for a couple of days of practice, which coincidentally came right around the time Bills star cornerback Tre’Davious White signed a new four-year, $70 million contract with Buffalo.
If Gilmore wanted a pay raise this season, it’s very likely that he will want more money next season too, which could lead to a possible holdout. New England may decide Gilmore is not worth the hassle of dealing with a holdout next offseason, which could lead to a trade of the cornerstone of the New England defense.
Bill Belichick is one of the best in the business when it comes to evaluating players based on future production, and not past performance. In the case of Gilmore, it’s very possible that last year’s performance was the peak of his career. This season, Gilmore has allowed a passer rating of 100.9, which is fourth-worst among NFL cornerbacks who have played 50 percent of snaps or more. If Gilmore wants more money in 2021 and beyond, he may have a difficult time getting it in New England.
What could trading Gilmore get New England in return? According to Breer, the Patriots would have a tough time getting higher than a second round pick in return for the reigning Defensive Player of the Year, on account of his age.
Where could Gilmore land? The Tennessee Titans are a team with playoff hopes and just enough remaining cap space in 2020 to fit in Gilmore’s contract for 2020, as he has around $7 million left in 2020 money, and the Titans have $7.5 million in cap space for the remainder of 2020.
The Arizona Cardinals are a team in the thick of a crowded NFC West divisional race that features lethal passing attacks in Seattle and Los Angeles. Adding Gilmore to a secondary featuring Patrick Peterson and Byron Murphy Jr. would be a big boost for a young Cardinals team down the stretch. However, Arizona has $6.5 million in cap space left in 2020, and would likely need to send back some salary to New England, or make a separate move, to facilitate a trade.
Both teams have second round picks to offer in return for Gilmore.
Sunday’s matchup in Orchard Park looms large, in the meantime. With the NFL trade deadline not coming until November 3 (you couldn’t pick literally any other day than this one, NFL?), the team can take this week to self-evaluate and determine if the playoffs are still an attainable goal this season, after Sunday’s divisional battle.
A loss on Sunday could spell the end of Gilmore’s time as a Patriot, and New England would be wise to explore a trade of the talented cornerback in order to build a better team for the future.
Enable breaking news notifications straight to your internet browser.
October 28, 2020 | 9:52 AM
Morning sports update: What Bill Belichick and NFL insiders have said about the Stephon Gilmore trade rumors
The Dodgers won the World Series on Tuesday, defeating the Rays in Game 6 by a 3-1 final score. Former Red Sox outfielder Mookie Betts — traded to Los Angeles in February from Boston — hit a home run to help the Dodgers win a championship for the first time since 1988.
Mookie with some insurance and the @Dodgers can taste it. #WorldSeries pic.twitter.com/vYFv18DMS5
— MLB (@MLB) October 28, 2020
And tonight, the Revolution take on the New York Red Bulls with a possible playoff berth on the line. If New England wins, they clinch a playoff spot for the second season in a row. Kickoff is set at 7 p.m.
The Stephon Gilmore trade rumors: It began before the 2020 season, when reports emerged that the Patriots explored trading 2019 Defensive Player of the Year Stephon Gilmore.
Now, with the Patriots at 2-4 and the NFL trade deadline looming (Nov. 3rd), the 30-year-old cornerback is potentially available for a deal. In addition, there is an unconfirmed report that Gilmore’s house is on the market.
The initial source of the recent Gilmore trade rumors was NFL reporter Albert Breer, who reasoned that — given Gilmore’s contract and the Patriots’ current position — a trade might make sense.
“They got to be real honest about where they are from a building standpoint,” Breer told NBC Sports Boston prior to the Patriots’ loss to the 49ers. “If they’re not going to compete for a championship — which I think is always going to be the bar as long as Bill Belichick’s here — you have to see what you can get for someone like Stephon Gilmore. Because I think chances are he’s not going to be on the team in 2021.
“They had to move some money from ’21 to ’20 to make him happy this year. He’ll want another raise next year, so I think when they did make the move to move that money up to ’20, there was an acknowledgement that he might not be around next year. And if he’s not going to be around next year, and you don’t think you’re going to compete for a championship this year, then it behooves you to take a look.
“The question then becomes what you’re willing to take for him,” Breer continujed. “Because I don’t think it’s going to be a first-round pick. I can give you guys a list of 10 guys who’ve gone for first-round picks over the last two years — every single one of those guys was 27 years old or younger. So, I don’t think you’re getting a first-round pick for him. But if you’re willing to move him for a second or a third, I think there could be a market out there for him.”
Could the Patriots trade reigning DPOY Stephon Gilmore? @AlbertBreer discusses what he’s heard on Pregame Live. pic.twitter.com/DgAXScyVte
— NBC Sports Boston (@NBCSBoston) October 25, 2020
NFL Network reporter Ian Rapoport, speaking with WEEI’s “The Greg Hill Show” on Wednesday morning, said that he’d heard the Gilmore trade rumors before the season.
“But I haven’t heard them recently,” Rapoport added, noting that “I haven’t gotten anything that’s imminent on Stephon Gilmore.”
Later on Wednesday, Bill Belichick was asked about if he expects Gilmore to be on the team’s roster beyond the trade deadline.
“I don’t know anything about those,” said Belichick of the rumors. Later in the press conference, the Patriots’ coach added some praise of Gilmore’s day-to-day work.
“Steph works hard,” Belichick told reporters. “He’s always ready to go. Changes up what he does based on our game plan, who we’re matched up against, the team we’re playing that particular week. He’s a very flexible player that understands what we’re trying to do and how it all fits together and works hard to do his part in it.”
Gilmore, who tweeted on Oct 22 that he “saw a lot of peoples true colors in 2020,” signed with the Patriots as a free agent in 2017 on a five-year, $65 million deal. He was a part of the team’s Super Bowl LIII victory, making a crucial fourth quarter interception of Rams quarterback Jared Goff.
Trivia: Mookie Betts has now hit home runs in World Series clinching games for multiple teams, becoming just the second player in MLB history to do so. Who was the other?
(Answer at the bottom).
Hint: He made cameos in several movies, including “Richie Rich,” “BASEketball,” and “The Naked Gun: From the Files of Police Squad!”
More from Boston.com:
Justin Turner was pulled from the World Series due to a positive COVID-19 test: Still, Turner was somehow allowed on the field to celebrate with teammates after the team won.
Some more stats on Mookie Betts in the World Series:
Mookie Betts joins Lenny Dykstra (1993) and Lou Brock (1968) as the only players with 4 SB and multiple HR in a World Series. pic.twitter.com/yxNbh221B3
— ESPN Stats & Info (@ESPNStatsInfo) October 28, 2020
On this day: In 2007, the Red Sox completed the sweep of the Rockies to win the World Series.
Series MVP Mike Lowell and pinch-hitter Bobby Kielty hit home runs to help power Boston’s offense, and Jonathan Papelbon was there to slam the door shut in the 9th inning, celebrating after the final out of a 4-3 win with customary enthusiasm.
Daily highlight: Marcus Thuram, son of French World Cup winner Lillian, scored against Real Madrid on Tuesday with an emphatic finish. The assist wasn’t bad either. Real rallied late to get a 2-2 draw against Thuram and Borussia Monchengladbach.
What a finish from Marcus Thuram! @borussia_en can he use this for his ID? 😂 pic.twitter.com/SUba6hTb8i
— Champions League on CBS Sports (@UCLonCBSSports) October 27, 2020
Trivia answer: Reggie Jackson
Enable breaking news notifications straight to your internet browser.
Hayden Bird, Boston.com Staff
October 28, 2020 | 10:38 AM
2 Coronavirus Stocks That Will Falter in a Market Crash
The ongoing race to make vaccines and therapies for the coronavirus has led to a tremendous amount of speculation in the market. For some stocks, these expectations have merely added fuel to the fire of a strong company’s robust returns for shareholders. For others, like Sorrento Therapeutics (NASDAQ:SRNE) and BioNTech (NASDAQ:BNTX), working on coronavirus products has created massively inflated prices that are vulnerable to melting down during a market crash.
Both stocks have grown more than 130% this year, but neither company has sales revenue from the successful commercialization of any pipeline project. Likewise, these companies aren’t anywhere near completing any of their coronavirus programs, so recurring revenue is not necessarily around the corner. As highly risky biotech stocks, their prices are largely determined by sentiment surrounding their future revenue — but there’s no guarantee that this revenue will ever come. Both stocks are vulnerable to losing a lot of their value in a market correction or crash, and neither is a safe harbor for investors under the best of conditions. Let’s analyze each company to understand why.
Image source: Getty Images.
For a biotech stock, Sorrento ticks all of the boxes that intrigue coronavirus investors. The company is trying to develop a coronavirus vaccine, a pair of diagnostic tests, and several different therapies that are catered to each stage of the disease’s clinical progression. This means that Sorrento is in theory exposed to several massive upsides which it could realize simultaneously if its research and development operations proceed as planned. But the chances of Sorrento ever making it big are slim, as all of these coronavirus programs are in early stages of development and the company’s financial situation is deteriorating.
Sorrento has trailing revenue of $35.54 million, $24.39 million in cash, and total debt of $220.84 million. Of that debt, $22.61 million is due in the short term. In the last 12 months, Sorrento spent $157.93 million. To stay in operation, the company also issued $79.34 million in new stock, leading to stock issuance totaling $196.94 million in the last year. To say that diluting its shareholder value at this rate is unsustainable would be a massive understatement — but aside from taking on even more debt, there doesn’t seem to be any other way for Sorrento to stay solvent in the short term. If the market is crashing, Sorrento is probably a stock that investors would want to sell, as its future is uncertain even at its present price.
^SPX data by YCharts
Unlike Sorrento, BioNTech has fewer coronavirus projects, and it isn’t in as dire a condition financially. BioNTech’s claim to fame in the coronavirus market is its vaccine project, which it’s pursuing under the watchful guidance of Pfizer (NYSE:PFE). BioNTech’s vaccine candidate is advancing quickly, and Pfizer has paid it $185 million already, ensuring that it isn’t about to run out of cash anytime soon.
Nonetheless, BioNTech’s other pipeline projects are still in their earliest stages, and it’s unlikely that they will be advancing very rapidly if the company’s energies are focused on the vaccine. BioNTech has also diluted its stock even more aggressively than Sorrento, raising 522.98 million Euros in the last 12 months while reporting cash outflows of 239.43 million Euros. This is a bad sign for potential investors, and it may also be indicative that the company is trying to take advantage of its inflated stock price while it still can.
Currently, BioNTech is trading at a trailing price-to-sales ratio in excess of 137, which is vastly higher than the biotech industry’s average price-to-sales ratio of 6.88. This means that for each dollar of the company’s sales revenue, BioNTech investors are paying $137, even though the overwhelming majority of other biotech stocks would cost them much closer to $6.88. If the market crashes again before its vaccine hits the market, BioNTech’s bloated valuation will face a reckoning, and its current shareholders are likely to be punished.
Author: Alex Carchidi
Stock Market News for Oct 28, 2020
Wall Street closed mostly lower on Tuesday owing to a record-high resurgence of coronavirus in the United States and Europe. Moreover, possibility of a Congressional deal for the second round of fiscal stimulus before the upcoming presidential election looks bleak. Mixed economic data also dented investors’ confidence. The Dow and the S&P 500 ended in the red while the Nasdaq Composite finished in green.
The Dow Jones Industrial Average (DJI) slipped 0.8% or 221.19 points to close at 27,463.19. Notably, 23 components of the 30-stock index ended in the red while 7 finished in green. The index is 3.8% away to become green year to date. However, the tech-laden Nasdaq Composite finished at 11,431.35, gaining 0.6% due to strong performance by large-cap technology stocks.
Meanwhile, the S&P 500 dropped 0.3% to end at 3,390.68. This was the broad-market index’s first close below 3,400 since Oct 6. The Energy Select Sector SPDR (XLE), the Industrials Select Sector SPDR (XLI) and the Financials Select Sector SPDR (XLF) tanked 1.3%, 2.2% and 1.8%, respectively. Notably, nine out of eleven sectors of the benchmark index closed in negative zone and two in positive zone.
For both the S&P 500 and the Nasdaq Composite, major gainer was Xilinx Inc. (XLNX – Free Report) that rallied 8.6% following the news that its rival chipmaker Advanced Micro Devices Inc. (AMD – Free Report) has agreed to buy the company for $35 billion. Advanced Micro Devices carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The fear-gauge CBOE Volatility Index (VIX) was up 2.7% to 33.35. A total of 8.8 billion shares were traded on Tuesday, lower than the last 20-session average of 9 billion. Decliners outnumbered advancers on the NYSE by a 1.68-to-1 ratio. On Nasdaq, a 1.40-to-1 ratio favored declining issues.
According to the Johns Hopkins University, daily coronavirus cases in the United States have risen a record high by an average of 69,967 over the past seven days. Per CNBC, more than 20 states reported record-high numbers of average daily new cases. Moreover, new cases are rising by 5% or more in 36 states. In Europe, the government of France has declared a public health state of emergency and the U.K. government is mulling a second national lockdown. Russia also saw a spike in new COVID-19 cases.
Despite three months of negotiations, the U.S. Congress failed to reach an amicable solution regarding the size and the scope of the second round of fiscal stimulus. Chances of a deal to reach before the U.S. presidential election is bleak as Senate Majority Leader Mitch McConnell adjourned the Senate until Nov 9. The first trench of $2.2 trillion stimulus ended on July. Several economic data have indicated that the U.S. economic recovery has slowed in absence of a fresh fiscal stimulus.
The Department of Commerce reported that durable goods orders jumped 1.9% in September from 0.4% in August. The consensus estimate was 0.4%. The core capital goods (orders for non-defense capital goods excluding aircraft) rose 1% in September. August’ core capital goods orders were revised upward to 2.1% from 1.9% reported earlier. In absolute terms, the core capital goods orders are now above the pre-pandemic level. Notably, economists used core capital goods orders as a closely watched proxy for business spending plans.
The S&P CoreLogic Case-Shiller National Home Price Index for August rose 5.7% annually compared with 4.8% in July. The 10-City Composite registered a gain of 4.7% compared with 3.5% in the previous month. The 20-City Composite climbed 5.2% year-over-year compared with 4.1% in July.
The Conference Board reported that consumer confidence for October came in at 100.9, missing the consensus estimate of 101.5. Meanwhile, September’s data was revised downward to 101.3 from 101.8 reported earlier. The present satisfaction sub-index (that gauges how consumers feel about the economy right now) increased to 104.6 in October from 98.9 in September. The expectations sub-index (gauge that assesses how Americans view the next six months) decreased to 98.4 in October from 102.9 in the previous month.
Concho Q3 Earnings Beat Estimates, Revenues Miss Mark
In addition to the companies you learned about above, we invite you to learn more about profiting from the upcoming presidential election. Trillions of dollars will shift into new market sectors after the votes are tallied, and investors could see significant gains. This report reveals specific stocks that could soar: 6 if Trump wins, 6 if Biden wins.
Check out the 2020 Election Stock Report >>
Author: Zacks Investment Research